Exelixis, Inc. (BIT:1EXEL)

Market Cap	9.84B
Revenue (ttm)	2.13B
Net Income (ttm)	595.43M
Shares Out	n/a
EPS (ttm)	2.04
PE Ratio	16.52
Forward PE	14.89
Dividend	n/a
Ex-Dividend Date	n/a

Volume	325
Average Volume	30
Open	37.70
Previous Close	40.15
Day's Range	37.30 - 37.70
52-Week Range	34.18 - 42.61
Beta	n/a
RSI	50.91
Earnings Date	Aug 5, 2025

About Exelixis

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1994
• Employees: 1,147
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1EXEL

Financial Performance

In 2024, Exelixis's revenue was $2.17 billion, an increase of 18.49% compared to the previous year's $1.83 billion. Earnings were $521.27 million, an increase of 150.89%.

Financial numbers in USD